RLAY
Relay Therapeutics, Inc.
Stock
$18.96+0.47 (+2.54%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $10M | $26M | $1.4M | $3.0M | $83M |
| R&D | $271M | $261M | $319M | $330M | $246M | $173M | $100M |
| Operating income | −$310M | −$303M | −$372M | −$373M | −$299M | −$365M | −$56M |
| Net income | −$286M | −$276M | −$338M | −$342M | −$291M | −$364M | −$52M |
| Diluted EPS | −$1.57 | −$1.61 | −$2.36 | −$2.79 | −$2.59 | −$3.82 | −$5.40 |
| Diluted shares | — | 171.6M | 142.9M | 122.6M | 112.2M | 95.1M | 42.6M |
| Revenue growth | — | +53.4% | −60.8% | +1,749.8% | −54.4% | −96.3% | — |
| Operating margin | −2,999.4% | −1,971.6% | −3,722.1% | −1,460.1% | −21,670.9% | −12,040.2% | −67.5% |
| Net margin | −2,763.6% | −1,800.6% | −3,374.7% | −1,338.7% | −21,036.1% | −12,012.9% | −63.4% |